

Savino Sciascia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787364/publications.pdf>

Version: 2024-02-01

270
papers

6,955
citations

61984

43
h-index

91884

69
g-index

273
all docs

273
docs citations

273
times ranked

6491
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <sc>APS ACTION</sc> International Clinical Database and Repository. Arthritis Care and Research, 2022, 74, 324-335.	3.4	39
2	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	1.9	26
3	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology, 2022, 61, 1928-1935.	1.9	15
4	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	2.0	9
5	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial” comment on: “Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus” by Chatzidionysiou<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e140-e140.	0.9	9
6	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nature Reviews Rheumatology, 2022, 18, 9-21.	8.0	21
7	Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. Autoimmunity Reviews, 2022, 21, 103030.	5.8	5
8	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
9	Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab. Frontiers in Medicine, 2022, 9, 819320.	2.6	4
10	Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease. Nephron, 2022, 146, 481-488.	1.8	4
11	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. Clinical and Experimental Rheumatology, 2022, 40, 575-580.	0.8	5
12	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	3.4	0
13	Dietary Patterns at the Individual Level through a Nutritional and Environmental Approach: The Case Study of a School Canteen. Foods, 2022, 11, 1008.	4.3	2
14	New Onset Biopsy-Proven Nephropathies after COVID Vaccination. American Journal of Nephrology, 2022, 53, 325-330.	3.1	32
15	Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy. Frontiers in Immunology, 2022, 13, 777134.	4.8	4
16	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. International Journal of Environmental Research and Public Health, 2022, 19, 5379.	2.6	2
17	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. Vaccines, 2022, 10, 663.	4.4	10
18	Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. Journal of Clinical Medicine, 2022, 11, 2977.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Histological Kidney Re-Evaluation after Daratumumab Monotherapy for AL Amyloidosis. Hemato, 2022, 3, 367-372.	0.6	0
20	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€“Registryâ€™). Lupus Science and Medicine, 2022, 9, e000633.	2.7	9
21	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Annals of the Rheumatic Diseases, 2022, 81, 1769-1772.	0.9	9
22	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	3.4	60
23	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis Care and Research, 2021, 73, 1804-1808.	3.4	7
24	Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. Journal of Nephrology, 2021, 34, 231-240.	2.0	2
25	Treatment of antiphospholipid syndrome. , 2021, , 621-628.		0
26	Efficacy of low or standard rituximab-based protocols and comparison to Ponticelliâ€™s regimen in membranous nephropathy. Journal of Nephrology, 2021, 34, 565-571.	2.0	18
27	EULAR recommendations for a core data set for pregnancy registries in rheumatology. Annals of the Rheumatic Diseases, 2021, 80, 49-56.	0.9	36
28	Health Disparities in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2021, 47, 119-132.	1.9	7
29	Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players?. European Journal of Clinical Investigation, 2021, 51, e13441.	3.4	6
30	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547.	2.0	19
31	Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology, 2021, 60, 1106-1113.	1.9	18
32	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. , 2021, , 109-134.		0
33	The effect of hydroxychloroquine on platelet activation in model experiments. Journal of Thrombosis and Thrombolysis, 2021, 52, 674-679.	2.1	3
34	Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. Journal of Oral Science, 2021, 63, 217-226.	1.7	13
35	Antibodies as risk factors for adverse maternal and foetal outcomes. , 2021, , 56-64.		0
36	Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. Rheumatology and Therapy, 2021, 8, 81-94.	2.3	11

#	ARTICLE	IF	CITATIONS
37	A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. Journal of Clinical Medicine, 2021, 10, 292.	2.4	5
38	Antiphospholipidic Antibodies in SARS-CoV2 Infection: Still a Lot to Learn. Medicina Interna (Bucharest, Romania: 1991), 2021, 18, 7-9.	0.0	0
39	Incidence of a First Thrombo-Embolitic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. Frontiers in Medicine, 2021, 8, 621590.	2.6	1
40	Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. Lupus, 2021, 30, 884-892.	1.6	3
41	Community Garden Initiatives Addressing Health and Well-Being Outcomes: A Systematic Review of Infodemiology Aspects, Outcomes, and Target Populations. International Journal of Environmental Research and Public Health, 2021, 18, 1943.	2.6	23
42	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. Expert Review of Clinical Immunology, 2021, 17, 395-406.	3.0	6
43	Antiphospholipid syndrome: the need for new international classification criteria. Expert Review of Clinical Immunology, 2021, 17, 385-394.	3.0	6
44	Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Medica, 2021, 112, 162-174.	0.9	12
45	A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. Kidney International Reports, 2021, 6, 1081-1087.	0.8	12
46	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	6.7	19
47	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports, 2021, 23, 45.	4.7	9
48	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus, 2021, 30, 1314-1326.	1.6	9
49	POS0172â€“...THROMBIN GENERATION ASSAY AND LUPUS ANTICOAGULANT IDENTIFY DIFFERENT POPULATIONS OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES. Annals of the Rheumatic Diseases, 2021, 80, 298.1-299.	0.9	1
50	Antiphospholipid Antibodies and Infection: Non Nova Sed Nove. Frontiers in Immunology, 2021, 12, 687534.	4.8	14
51	The role of antirheumatics in patients with COVID-19. Lancet Rheumatology, The, 2021, 3, e447-e459.	3.9	36
52	Antiphospholipid antibodies and cerebrovascular thrombosis in the pediatric population: Few answers to many questions. Lupus, 2021, 30, 1365-1377.	1.6	0
53	Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. Orphanet Journal of Rare Diseases, 2021, 16, 280.	2.7	8
54	Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology. Thrombosis Research, 2021, 202, 100-103.	1.7	6

#	ARTICLE	IF	CITATIONS
55	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. Immunologic Research, 2021, 69, 372-377.	2.9	4
56	A new challenge for lupus nephritis management: Induction therapy without immunosuppressive maintenance regimen. Autoimmunity Reviews, 2021, 20, 102844.	5.8	5
57	A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome. Kidney International, 2021, 100, 740-742.	5.2	4
58	Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). European Journal of Internal Medicine, 2021, 92, 134-136.	2.2	7
59	Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. American Journal of Nephrology, 2021, 52, 559-571.	3.1	15
60	Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. Lancet Rheumatology, The, 2021, 3, e832.	3.9	13
61	Moving toward personalized approaches in the management of lupus nephritis. Expert Opinion on Biological Therapy, 2021, 21, 1547-1550.	3.1	1
62	Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. Frontiers in Immunology, 2021, 12, 769785.	4.8	6
63	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Advances in Rheumatology, 2021, 61, 64.	1.7	0
64	The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. Reumatismo, 2021, 73, .	0.9	2
65	Quality of life measures in Systemic Lupus Erythematosus: A systematic review. Reumatismo, 2021, 73, .	0.9	2
66	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). Clinical and Experimental Rheumatology, 2021, 39, 938-946.	0.8	1
67	The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes. Clinical and Experimental Rheumatology, 2021, 39, 1071-1076.	0.8	2
68	An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 125-128.	0.8	3
69	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
70	An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39, 125-128.	0.8	11
71	The Challenging Management of Cancer: An Immunonephrologist's Perspective. Kidney and Blood Pressure Research, 2021, 46, 114-120.	2.0	2
72	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. Autoimmunity Reviews, 2020, 19, 102449.	5.8	10

#	ARTICLE	IF	CITATIONS
73	P1251THROMBIN GENERATION ASSAY: A POTENTIAL TOOL TO STRATIFY THROMBOTIC RISK IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
74	Treatment of antiphospholipid syndrome. Clinical Immunology, 2020, 221, 108597.	3.2	11
75	Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thrombosis Research, 2020, 196, 432-434.	1.7	20
76	Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly. Kidney and Blood Pressure Research, 2020, 45, 784-791.	2.0	3
77	Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis. Autoimmunity Reviews, 2020, 19, 102622.	5.8	0
78	Clinical exome sequencing is a powerful tool in the diagnostic flow of monogenic kidney diseases: an Italian experience. Journal of Nephrology, 2020, 34, 1767-1781.	2.0	11
79	Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement. Immunologic Research, 2020, 68, 340-352.	2.9	9
80	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus, 2020, 29, 1353-1363.	1.6	28
81	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmunity Reviews, 2020, 19, 102641.	5.8	13
82	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatology, The, 2020, 2, e735-e736.	3.9	3
83	Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. Journal of Clinical Medicine, 2020, 9, 3232.	2.4	7
84	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. Lupus, 2020, 29, 1601-1615.	1.6	27
85	Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. Italian Journal of Pediatrics, 2020, 46, 130.	2.6	14
86	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. Journal of Thrombosis and Haemostasis, 2020, 18, 2921-2928.	3.8	7
87	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. International Journal of Molecular Sciences, 2020, 21, 9551.	4.1	11
88	Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies. Biomedicines, 2020, 8, 622.	3.2	6
89	P0206RITUXIMAB IN ADULT ONSET OF IGA VASCULITIS WITH SEVERE RENAL INVOLVEMENT: A SINGLE CENTER EXPERIENCE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
90	P0244OVERTURNING THE CONVENTIONAL PYRAMID OF AL AMYLOIDOSIS MANAGEMENT: DARATUMUMAB ADMINISTERED AS MONOTHERAPY IN SEVERE PATIENTS WITH BIOPSY PROVEN RENAL INVOLVEMENT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

#	ARTICLE	IF	CITATIONS
91	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp® A Usability Study. International Journal of Environmental Research and Public Health, 2020, 17, 3469.	2.6	5
92	Hydroxychloroquine reduces IL-6 and pro-thrombotic status. Autoimmunity Reviews, 2020, 19, 102555.	5.8	7
93	CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. International Journal of Molecular Sciences, 2020, 21, 4129.	4.1	20
94	Antiphospholipid Syndrome Is Still a Rare Disease—Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al. Arthritis and Rheumatology, 2020, 72, 1774-1776.	5.6	12
95	Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Internal and Emergency Medicine, 2020, 15, 861-863.	2.0	76
96	Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome. Thrombosis and Haemostasis, 2020, 120, 592-598.	3.4	41
97	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. Autoimmunity Reviews, 2020, 19, 102488.	5.8	5
98	Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global Antiphospholipid Syndrome Score. Seminars in Arthritis and Rheumatism, 2020, 50, 553-556.	3.4	13
99	Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. Journal of Nephrology, 2020, 33, 757-762.	2.0	6
100	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. Rheumatology, 2020, 59, 2412-2418.	1.9	19
101	Filling the gap in antiphospholipid syndrome diagnosis: a patient's story. Lupus, 2020, 29, 236-238.	1.6	4
102	Value of colchicine as treatment for recurrent oral ulcers: A systematic review. Journal of Oral Pathology and Medicine, 2020, 49, 731-740.	2.7	17
103	Global antiphospholipid syndrome score and anti-β2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. Lupus, 2020, 29, 676-685.	1.6	13
104	OP0148...MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 94-95.	0.9	3
105	Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review. European Journal of Rheumatology, 2020, 7, 31-34.	0.6	14
106	FRI0589...CLINICAL ACCURACY OF ANTI-PHOSPHATIDYL SERINE/PROTHROMBIN AND ANTI-BETA2GLYCOPROTEIN I DOMAIN I FOR PREDICTING CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME. Annals of the Rheumatic Diseases, 2020, 79, 899.1-900.	0.9	0
107	AB0409...APL PREVALENCE IN WOMEN WITH LATE PREGNANCY COMPLICATION AND LOW-RISK FOR CHROMOSOMAL ABNORMALITIES. Annals of the Rheumatic Diseases, 2020, 79, 1504.1-1505.	0.9	0
108	Antiphospholipid Antibodies and Fertility: No Impact on Ovarian Reserve in Premenopausal Women. Journal of Clinical Rheumatology and Immunology, 2020, 20, 4-8.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 529-532.	0.8	196
110	Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 195-200.	0.8	3
111	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (<scp>APS</scp>) in the <scp>APS</scp> Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 656-661.	2.3	29
112	The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience. <i>European Journal of Internal Medicine</i> , 2019, 68, e12-e14.	2.2	1
113	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	3.8	9
114	Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6308-6318.	3.6	15
115	FP110THE CYCLOPHOSPHAMIDE-SPARING EFFECT OF AN INTENSIFIED B-CELLS DEPLETION PROTOCOL IN ANCA-ASSOCIATED VASCULITIS: A CASE-CONTROL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
116	FP239EFFICACY OF LOW OR STANDARD DOSE RITUXIMAB AS COMPARED TO PONTICELLIâ€™S REGIMEN IN MEMBRANOUS NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
117	IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. <i>Frontiers in Medicine</i> , 2019, 6, 211.	2.6	5
118	SP143PERCUTANEOUS NATIVE RENAL BIOPSY AS A SAFE PROCEDURE IN OUTPATIENT WITH SYSTEMIC AUTOIMMUNE DISEASES: A MONOCENTRIC COHORT. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
119	Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1920-1926.	3.4	13
120	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	1.7	13
121	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008.	1.9	10
122	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	3.4	79
123	Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. <i>Rheumatology</i> , 2019, 58, 1870-1872.	1.9	1
124	Long-term evaluation of pemphigus vulgaris: A retrospective consideration of 98 patients treated in an oral medicine unit in north-west Italy. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 406-412.	2.7	15
125	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	4.8	34
126	THU0602â€¦THE ROLE OF INFRARED THERMOGRAPHY IN THE ASSESSMENT OF PERIPHERAL VASCULOPATHY AND IN THE THERAPEUTIC MANAGEMENT OF SYSTEMIC SCLEROSIS PATIENTS TREATED WITH SYNTHETIC PROSTANOIDS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	Acute kidney injury associated with glomerular diseases. <i>Current Opinion in Critical Care</i> , 2019, 25, 573-579.	3.2	11
128	The dilemma of treating hepatitis C virus-associated cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2019, 31, 499-504.	4.3	5
129	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1004-1006.	0.9	23
130	Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 741-744.	3.4	12
131	Nailfold Capillaroscopy Patterns. <i>Israel Medical Association Journal</i> , 2019, 21, 497-498.	0.1	0
132	Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic". <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961875834.	0.6	2
133	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	3.4	62
134	Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. <i>Rheumatology</i> , 2018, 57, 661-665.	1.9	49
135	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	3.4	42
136	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
137	Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. <i>Lupus</i> , 2018, 27, 1393-1394.	1.6	7
138	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	3.5	30
139	The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. <i>European Journal of Neurology</i> , 2018, 25, 320-325.	3.3	24
140	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , 2018, 27, 399-406.	1.6	51
141	Prevalence and Thrombotic Risk Assessment of Anti-Î22 Glycoprotein I Domain I Antibodies: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 466-474.	2.7	60
142	Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223302.	0.5	1
143	Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. <i>Oncotarget</i> , 2018, 9, 28799-28804.	1.8	23
144	Thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 21-27.	1.6	3

#	ARTICLE	IF	CITATIONS
145	Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?. Expert Review of Clinical Immunology, 2018, 14, 877-879.	3.0	5
146	Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Annals of the Rheumatic Diseases, 2018, 77, 1694-1695.	0.9	28
147	Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients. Thrombosis Research, 2018, 170, 28-31.	1.7	1
148	Recent advances in the management of systemic lupus erythematosus. F1000Research, 2018, 7, 970.	1.6	23
149	Multifocal avascular osteonecrosis despite appropriate anticoagulation therapy in a patient with systemic lupus erythematosus and antiphospholipid syndrome. BMJ Case Reports, 2018, 2018, bcr-2018-225532.	0.5	5
150	Thymic stromal lymphopoietin in human pancreatic ductal adenocarcinoma: expression and prognostic significance. Oncotarget, 2018, 9, 32795-32809.	1.8	3
151	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. European Journal of Rheumatology, 2018, 5, 92-95.	0.6	14
152	Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Internal and Emergency Medicine, 2017, 12, 1-7.	2.0	28
153	Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. Autoimmunity Reviews, 2017, 16, 287-293.	5.8	60
154	Global Antiphospholipid Syndrome Score. Handbook of Systemic Autoimmune Diseases, 2017, 12, 215-219.	0.1	0
155	Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review. Autoimmunity Reviews, 2017, 16, 469-477.	5.8	34
156	Lupus nephritis and pregnancy outcome. Autoimmunity Reviews, 2017, 16, 433-434.	5.8	8
157	Infodemiology of systemic lupus erythematosus using Google Trends. Lupus, 2017, 26, 886-889.	1.6	32
158	Expanding the therapeutic options for renal involvement in lupus: ecilizumab, available evidence. Rheumatology International, 2017, 37, 1249-1255.	3.0	61
159	Antiphospholipid antibodies: crossroads between autoimmunity and infections?. Internal and Emergency Medicine, 2017, 12, 557-558.	2.0	0
160	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Seminars in Thrombosis and Hemostasis, 2017, 43, 562-571.	2.7	89
161	The adjusted Global Antiphospholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. International Journal of Cardiology, 2017, 240, 72-77.	1.7	48
162	Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials. Clinical Drug Investigation, 2017, 37, 519-524.	2.2	30

#	ARTICLE	IF	CITATIONS
163	Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. <i>BioDrugs</i> , 2017, 31, 37-49.	4.6	30
164	What can Google and Wikipedia can tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus. <i>International Journal of Medical Informatics</i> , 2017, 107, 65-69.	3.3	25
165	Current insights in obstetric antiphospholipid syndrome. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 397-403.	2.0	41
166	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	5.8	19
167	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <i>Internal and Emergency Medicine</i> , 2017, 12, 1101-1108.	2.0	14
168	Hydroxychloroquine and the eye: an old unsolved problem. <i>Eye</i> , 2017, 31, 1744-1744.	2.1	2
169	High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. <i>American Journal of Nephrology</i> , 2017, 46, 108-113.	3.1	24
170	The Cutaneous Spectrum of Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 291-305.	6.5	83
171	Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. <i>Nature Reviews Rheumatology</i> , 2017, 13, 548-560.	8.0	153
172	How I treat patients with systemic sclerosis in clinical practice. <i>Autoimmunity Reviews</i> , 2017, 16, 1024-1028.	5.8	20
173	Immunological Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 497-509.	1.6	2
174	Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. <i>BMJ Open</i> , 2017, 7, e015243.	1.9	26
175	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1923-1932.	2.4	60
176	Radiotherapy in patients with HIV: current issues and review of the literature. <i>Lancet Oncology</i> , The, 2017, 18, e379-e393.	10.7	15
177	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.8	1
178	AB1014â€¦Safety of outpatient percutaneous native renal biopsy in patients with systemic autoimmune diseases: results from a monocentric cohort. , 2017, , .		0
179	The â€œ4 plus 2â€•rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. <i>Oncotarget</i> , 2017, 8, 52072-52077.	1.8	15
180	The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. <i>Oncotarget</i> , 2017, 8, 41764-41777.	1.8	28

#	ARTICLE	IF	CITATIONS
181	Disease and Risk Measurement Criteria in Antiphospholipid Syndrome. , 2017, , 189-199.		0
182	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Thrombosis and Haemostasis, 2016, 115, 285-290.	3.4	66
183	Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. American Journal of Nephrology, 2016, 43, 251-260.	3.1	38
184	Antiphospholipid syndrome. Best Practice and Research in Clinical Rheumatology, 2016, 30, 133-148.	3.3	48
185	Autoantibodies and Biomarkers: Diagnostic Aspects. Rare Diseases of the Immune System, 2016, , 47-59.	0.1	0
186	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clinical and Molecular Allergy, 2016, 14, 6.	1.8	37
187	Patients with antiphospholipid syndrome and thrombotic recurrences: A real world observation (the Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	40
188	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology, 2016, 55, 1726-1735.	1.9	29
189	Emerging therapies in systemic lupus erythematosus: from clinical trial to the real life. Expert Review of Clinical Pharmacology, 2016, 9, 681-694.	3.1	4
190	New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. Autoimmunity Reviews, 2016, 15, 529-538.	5.8	64
191	Radiotherapy in patients with connective tissue diseases. Lancet Oncology, The, 2016, 17, e109-e117.	10.7	42
192	The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. American Journal of Obstetrics and Gynecology, 2016, 214, 273.e1-273.e8.	1.3	138
193	Antiphospholipid Antibodies and Syndrome: Complexities in Diagnosis and Management. , 2016, , 485-494.		0
194	Treatment of Antiphospholipid Syndrome. , 2016, , 543-549.		0
195	Immunogenetics of complement in mixed cryoglobulinaemia. Clinical and Experimental Rheumatology, 2016, 34, S12-5.	0.8	6
196	FRIO425â€¦The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 581.1-581.	0.9	0
197	Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 476-477.	1.0	49
198	Use of Intravenous Immunoglobulin in Patients With Active Vasculitis Associated With Concomitant Infection. Journal of Clinical Rheumatology, 2015, 21, 35-37.	0.9	5

#	ARTICLE	IF	CITATIONS
199	Thematic issue: Biologics in autoimmune diseases. <i>International Immunopharmacology</i> , 2015, 27, 179.	3.8	1
200	Upcoming biological therapies in systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2015, 27, 189-193.	3.8	14
201	Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 597.	1.0	0
202	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.	0.9	124
203	Biologics for the treatment of systemic lupus erythematosus: current status and emerging therapies. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 109-116.	3.0	41
204	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015, 14, 401-414.	5.8	194
205	Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?. <i>International Immunopharmacology</i> , 2015, 27, 220-223.	3.8	7
206	Rheumatoid arthritis: Biological therapy other than anti-TNF. <i>International Immunopharmacology</i> , 2015, 27, 185-188.	3.8	32
207	OP0188...Impact of Hydroxychloroquine Treatment on Pregnancy Outcome in Patients with Antiphospholipid Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 143.1-143.	0.9	0
208	A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment" Clinical response compared to literature and immunological re-assessment. <i>Autoimmunity Reviews</i> , 2015, 14, 1123-1130.	5.8	52
209	Antiphospholipid Syndrome and the Kidney. <i>Seminars in Nephrology</i> , 2015, 35, 478-486.	1.6	66
210	The global anti-phospholipid syndrome score in primary APS. <i>Rheumatology</i> , 2015, 54, 134-138.	1.9	87
211	Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: Case series and review of the literature. <i>Autoimmunity Reviews</i> , 2015, 14, 36-42.	5.8	22
212	Editorial paper Lupus and pregnancy in the 21st century. <i>Reumatologia</i> , 2014, 1, 1-3.	1.1	1
213	Thrombotic Risk Assessment in Systemic Lupus Erythematosus: Validation of the Global Antiphospholipid Syndrome Score in a Prospective Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1915-1920.	3.4	50
214	Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 354-364.	3.4	223
215	Targeted therapy in antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2014, 26, 269-275.	4.3	17
216	Renal involvement in antiphospholipid syndrome. <i>Nature Reviews Nephrology</i> , 2014, 10, 279-289.	9.6	84

#	ARTICLE	IF	CITATIONS
217	Anticardiolipin Antibodies. , 2014, , 735-739.		0
218	New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/PT) Antibodies. Current Rheumatology Reports, 2014, 16, 415.	4.7	30
219	Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Lupus, 2014, 23, 1286-1287.	1.6	20
220	New Oral Anticoagulants in the Management of Venous Thromboembolism: A Major Advance?. European Journal of Vascular and Endovascular Surgery, 2014, 48, 487-488.	1.5	2
221	Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. Journal of Neurology, 2014, 261, 1706-1714.	3.6	86
222	Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. Lupus, 2014, 23, 1309-1312.	1.6	18
223	Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. Thrombosis Research, 2014, 133, 451-454.	1.7	25
224	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930.	5.8	224
225	The Future Potential of Biosimilars Targeting B-Cells. Milestones in Drug Therapy, 2014, , 277-284.	0.1	0
226	Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clinical and Experimental Rheumatology, 2014, 32, 41-7.	0.8	20
227	Resolutive pulmonary endarterectomy in a non-compliant patient with systemic lupus erythematosus and antiphospholipid syndrome. Rheumatology International, 2013, 33, 1889-1893.	3.0	2
228	Is it time for biosimilars in autoimmune diseases?. Autoimmunity Reviews, 2013, 12, 954-957.	5.8	22
229	Management of infection in systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2013, 27, 377-389.	3.3	34
230	The clinical relevance of IgA anticardiolipin and IgA anti- β_2 glycoprotein I antiphospholipid antibodies. Autoimmunity Reviews, 2013, 12, 421-425.	5.8	69
231	The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmunity Reviews, 2013, 12, 821-825.	5.8	44
232	Common variable immunodeficiency: Crossroads between infections, inflammation and autoimmunity. Autoimmunity Reviews, 2013, 12, 796-801.	5.8	49
233	Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmunity Reviews, 2013, 12, 426-429.	5.8	58
234	Long-term Follow-up of Young Adults With Stroke. JAMA - Journal of the American Medical Association, 2013, 310, 321.	7.4	1

#	ARTICLE	IF	CITATIONS
235	Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 142-143.	0.9	33
236	GAPSS: the Global Anti-Phospholipid Syndrome Score. <i>Rheumatology</i> , 2013, 52, 1397-1403.	1.9	248
237	Antiphosphatidylserine/Prothrombin Antibodies in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 1620-1620.	2.0	0
238	OP0212â€¦Very Long-Term Effects of the â€œ4 Plus 2 Infusion Protocolâ€•of Rituximab Alone in Patients with HCV-Associated Mixed Cryoglobulinemia with Diffuse Membranoproliferative Glomerulonephritis, Severe Polyneuropathy and Necrotic Ulcers of Skin. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A124.1-A124.	0.9	0
239	Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. <i>Thrombosis and Haemostasis</i> , 2013, 109, 207-213.	3.4	58
240	High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 871.1-873.	2.0	2
241	Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. <i>Lupus</i> , 2012, 21, 806-809.	1.6	32
242	Systemic lupus erythematosus and infections: Clinical importance of conventional and upcoming biomarkers. <i>Autoimmunity Reviews</i> , 2012, 12, 157-163.	5.8	63
243	Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 273-277.	2.9	34
244	Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2512-2518.	3.8	96
245	Catastrophic antiphospholipid syndrome (CAPS). <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 535-541.	3.3	44
246	The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). <i>Thrombosis Research</i> , 2012, 130, 914-918.	1.7	16
247	8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. <i>Inflammation Research</i> , 2012, 61, 809-816.	4.0	27
248	Health Literacy and Discharge Instruction Adherence. <i>Journal of General Internal Medicine</i> , 2012, 27, 273-273.	2.6	9
249	Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. <i>Journal of Nephrology</i> , 2012, 25, 198-203.	2.0	22
250	Medical Students' Attitudes About Mental Illness. <i>Psychiatric Services</i> , 2012, 63, 836.	2.0	2
251	Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 409-13.	0.8	31
252	Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3987-3992.	0.7	61

#	ARTICLE	IF	CITATIONS
253	Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. American Journal of Nephrology, 2011, 34, 175-180.	3.1	35
254	Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus, 2011, 20, 1106-1108.	1.6	33
255	Exhaled breath condensate nitrates, but not nitrites or FENO, relate to asthma control. Respiratory Medicine, 2011, 105, 1007-1013.	2.9	24
256	Medical Students Need Training to Approach Chronic Pain. Pain Medicine, 2011, 12, 1692-1692.	1.9	0
257	How to improve our ability to predict adverse events in major surgery of SLE patients?. Autoimmunity Reviews, 2011, 10, 525-526.	5.8	1
258	Antiphospholipid syndrome and relapsing polychondritis: an unusual association. Lupus, 2011, 20, 1336-1337.	1.6	7
259	Unexplained chronic cough and vitamin B-12 deficiency. American Journal of Clinical Nutrition, 2011, 93, 542-548.	4.7	24
260	Interleukin 6 Blockade as Steroid-sparing Treatment for 2 Patients with Giant Cell Arteritis: Figure 1.. Journal of Rheumatology, 2011, 38, 2080-2081.	2.0	52
261	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1083-1086.	0.9	178
262	Risk Scale for the diagnosis of antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1517-1518.	0.9	43
263	Chronic Buddâ€Chiari Syndrome, Abdominal Varices, and Caput Medusae in 2 Patients With Antiphospholipid Syndrome. Journal of Clinical Rheumatology, 2010, 16, 302.	0.9	10
264	Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. Clinical and Experimental Allergy, 2010, 40, 1642-1647.	2.9	36
265	Increased oral nitric oxide in obstructive sleep apnoea. Respiratory Medicine, 2010, 104, 316-320.	2.9	31
266	Prioritisation of health research. Lancet, The, 2010, 376, 513-514.	13.7	0
267	Neonatal lupus in triplet pregnancy of a patient with undifferentiated connective tissue disease evolving to systemic lupus erythematosus. Lupus, 2009, 18, 368-371.	1.6	3
268	Osteonecrosis and Antiphospholipid Antibodies. Internal Medicine, 2009, 48, 737-738.	0.7	2
269	Exhaled Nitric Oxide and Nitric Oxide Synthase Expression in Hodgkin's Disease. International Journal of Immunopathology and Pharmacology, 2009, 22, 1027-1034.	2.1	9
270	Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease. Frontiers in Immunology, 0, 13, .	4.8	0